Skip to main content
. 2016 Aug 4;6:30741. doi: 10.1038/srep30741

Table 1. Clinical and biochemical characteristics.

  Control Very early Early Late p valuea p valueb
n = 56 n = 81 n = 304 n = 349
Risk factors
Age (year) 41.1 ± 2.9 41.3 ± 3.5 54.0 ± 5.1 65.3 ± 6.7 0.737 <0.001
Male, n (%) 46 (82.1) 73 (90.1) 167 (54.9) 284 (81.4) 0.204 <0.001
BMI (kg/m2) 25.7 ± 4.1 27.1 ± 3.5 25.7 ± 3.2 25.5 ± 3.5 0.026 <0.001
SBP (mm Hg) 120.3 ± 15.3 121.8 ± 12.5 129.0 ± 16.8 131.0 ± 17.7 0.547 <0.001
DBP (mm Hg) 78.9 ± 10.7 80.5 ± 12.0 80.5 ± 11.4 77.8 ± 11.1 0.421 0.005
Smoking, n (%) 27 (48.2) 39 (48.1) 117 (38.5) 125 (35.8) 0.122 <0.001
Hypertension, n (%) 16 (28.6) 46 (56.8) 193 (63.5) 233 (66.8) 0.002 0.223
DM, n (%) 7 (12.5) 16 (19.8) 75 (24.7) 105 (30.1) 0.354 0.096
Dyslipidemia, n (%) 28 (50.0) 57 (70.4) 184 (60.5) 204 (58.5) 0.020 0.141
Family history, n (%) 9 (16.1) 20 (24.7) 74 (24.3) 49 (14.0) 0.289 0.002
Laboratory and clinical test
D-dimer (μg/mL) 0.26 ± 0.16 0.27 ± 0.15 0.35 ± 0.32 0.43 ± 0.40 0.816 <0.001
WBC count (109/L) 6.45 ± 1.89 6.58 ± 1.76 6.29 ± 1.67 6.24 ± 1.73 0.682 0.266
ESR (mm/h) 4.5 (2–10) 5 (2–8) 7 (3–13) 7 (3–13) 0.825 0.004
hs-CRP (mg/L) 1.07 (0.64–2.19) 1.37 (0.68–2.69) 1.49 (0.75–2.99) 1.59 (0.68–3.31) 0.313 0.773
Fibrinogen (g/L) 2.86 ± 0.65 3.04 ± 0.77 3.09 ± 0.78 3.18 ± 0.84 0.150 0.223
LVEF (%) 67.1 ± 5.4 65.8 ± 7.3 64.9 ± 7.4 64.8 ± 7.6 0.251 0.558
Prior drug treatment
Aspirin, % (n) 10 (17.9) 32 (39.5) 123 (40.5) 151 (43.3) 0.008 0.703
Beta-blocker, % (n) 8 (14.3) 19 (23.5) 60 (19.7) 79 (22.6) 0.199 0.604
ACEI, % (n) 1 (1.8) 3 (3.7) 17 (5.6) 33 (9.5) 0.645 0.071
ARB, % (n) 2 (3.6) 9 (11.1) 27 (8.9) 48 (13.8) 0.199 0.148
CCB, % (n) 5 (8.9) 12 (14.8) 65 (21.4) 88 (25.2) 0.430 0.109

Data are expressed as mean ± SD or n (%). The bold values indicated statistical significance. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; WBC, white blood cell; ESR, erythrocyte sedimentation rate; hs-CRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. p valuea for very early CAD vs. control group. p valueb for very early CAD vs. early vs. late group.